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Abstract
Progranulin (PGRN) is a protein encoded by the GRN gene with multiple identified functions including as a
neurotrophic factor, tumorigenic growth factor, anti-inflammatory cytokine and regulator of lysosomal function. A
single mutation in the human GRN gene resulting in reduced PGRN expression causes types of frontotemporal lobar
degeneration resulting in frontotemporal dementia. Prosaposin (PSAP) is also a multifunctional neuroprotective
secreted protein and regulator of lysosomal function. Interactions of PGRN and PSAP affect their functional properties.
Their roles in Alzheimer’s disease (AD), the leading cause of dementia, have not been defined. In this report, we
examined in detail the cellular expression of PGRN in middle temporal gyrus samples of a series of human brain cases
(n = 45) staged for increasing plaque pathology. Immunohistochemistry showed PGRN expression in cortical neurons,
microglia, cerebral vessels and amyloid beta (Aβ) plaques, while PSAP expression was mainly detected in neurons and
Aβ plaques, and to a limited extent in astrocytes. We showed that there were increased levels of PGRN protein in AD
cases and corresponding increased levels of PSAP. Levels of PGRN and PSAP protein positively correlated with amyloid
beta (Aβ), with PGRN levels correlating with phosphorylated tau (serine 205) levels in these samples. Although PGRN
colocalized with lysosomal-associated membrane protein-1 in neurons, most PGRN associated with Aβ plaques did not.
Aβ plaques with PGRN and PSAP deposits were identified in the low plaque non-demented cases suggesting this was
an early event in plaque formation. We did not observe PGRN-positive neurofibrillary tangles. Co-immunoprecipitation
studies of PGRN from brain samples identified only PSAP associated with PGRN, not sortilin or other known PGRN-
binding proteins, under conditions used. Most PGRN associated with Aβ plaques were immunoreactive for PSAP
showing a high degree of colocalization of these proteins that did not change between disease groups. As PGRN
supplementation has been considered as a therapeutic approach for AD, the possible involvement of PGRN and PSAP
interactions in AD pathology needs to be further considered.
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Tangles, Interactions
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Introduction
Alzheimer’s disease (AD) is the most frequent cause of de-
mentia in elderly populations and currently affecting an
estimated 47 million people worldwide [1], but as the ages
of populations in most countries are increasing, the inci-
dence of AD will significantly increase. The brains of AD-
affected subjects show accumulations of amyloid beta
(Aβ) plaques and neurofibrillary tangles (NFT), the hall-
mark pathological features of this disease [2]. Preventing
the formation of these pathological structures is consid-
ered the key to preventing cognitive decline, the main
clinical feature of AD, but the mechanisms and sequence
of events leading to the accumulation of plaques and tan-
gles, neuronal death and cognitive decline are not fully
understood. To date, in spite of promising experimental
data in AD animal models, therapies to prevent or remove
Aβ have generally had limited effects in clinical trials to
slow down cognitive decline [3–5]; other approaches are
also needed.
Progranulin (PGRN) is a glycosylated protein of 75–80
kDa that can be secreted or transported to lysosomes [6]. It
is expressed in many different tissues and cell-types [7].
PGRN protein is composed of seven and a half repeats of a
highly conserved cysteine-containing motif that can be
cleaved into granulin peptides (A-G), some with proinflam-
matory properties [8]. In brain, PGRN has been demon-
strated to regulate neuroinflammation [9, 10], neurite
branching and outgrowth [11, 12], and lysosomal function
[13, 14]. The role of PGRN in AD has attracted attention in
recent years since the discovery that mutations in GRN, the
gene for progranulin, is one cause of frontotemporal de-
mentia (FTD) resulting from frontotemporal lobar degener-
ation (FTLD) [15, 16]. In FTD, loss of function mutations
in the GRN gene resulting in significantly reduced levels of
PGRN protein lead to neurodegeneration [15]. It has been
hypothesized that reduced PGRN results in neurodegenera-
tion due to enhanced neuroinflammation [10, 17]. The
mechanism of reduced PGRN causing enhanced neurode-
generation in FTD and AD has been investigated using
gene deletion rodent models but with conflicting results de-
pending on the model [18–22]. Complete loss of PGRN re-
sults in enhanced neuroinflammation and disturbance of
lysosomal function, but the clinical phenotypes of mice
with heterozygous GRN deletion were variable [13, 23, 24].
Increasing PGRN levels in animal models of FTD, AD and
Parkinson’s disease (PD) have been reported to reduce both
pathological and clinical features [19, 23, 25–27]. However,
there are increased levels of PGRN protein in human AD-
affected brains and AD mouse models [19]. It has been sug-
gested that the onset of AD might be caused by a drop in
PGRN levels prior to the end-stage increase, but this has
only been demonstrated in AD mouse models not human
subjects [19]. The single nucleotide polymorphism (SNP)
rs5848 (T) allele has been associated with an increased risk
of AD due to its effect on PGRN protein levels, but these
effects were not large [28, 29]. Biomarker studies of PGRN
levels in human cerebrospinal fluid (CSF) and plasma in
AD subjects have shown changes with disease progression
but limited diagnostic utility [28, 30]. While most experi-
mental studies on PGRN in brain have employed animal
models of FTD with single mutation or GRN gene knock-
out, the number of studies relating to PGRN and AD are
limited, but one feature observed in studies of AD trans-
genic mice and human brain samples was that PGRN accu-
mulated around Aβ plaques [19, 31–34]. An additional
study that employed granulin domain-specific antibodies
showed immunoreactivity of neurons, microglia and struc-
tures associated with plaques [35].
Prosaposin (PSAP) is also a lysosomal regulatory protein
with significant neuroprotective properties [36–38]. Re-
cent studies have shown biochemical interactions between
PGRN and PSAP, with these interactions affecting the
trafficking of these proteins to lysosomes [39–41]. There
were reduced levels of PSAP in neurons of GRN-deficient
mice and in samples from FTD patients with GRN muta-
tions [42]. Transgenic mice with reduced PSAP expression
demonstrated similar pathological and behavioral changes
as GRN gene-deficient mice [42]. PSAP deficiencies in
mice led to significant impairment of PGRN trafficking to
lysosomes but increased circulating levels of PGRN [41].
Experimental models of neuronal injury resulted in in-
creased levels of PSAP in neurons and microglia [38, 42,
43]. The interactions of PGRN and PSAP are complex as
both PSAP reduction and overexpression resulted in ele-
vated levels of extracellular/secreted PGRN in different
cellular models [4]. Overexpression of PSAP increased the
concentration of PGRN oligomers, while PSAP knock-
down increased concentrations of PGRN monomers [39].
These interactions affecting the levels, localization and ag-
gregation of PGRN might have significant effects on its
different biological activities. A recent proteomics study of
CSF identified PSAP as a biomarker to discriminate be-
tween preclinical AD and control cases [44].
As a result of the previous reports of increased PGRN
expression in AD brains in contrast to the deficits occur-
ring in FTD due to GRN mutations, detailed investigations
using immunohistochemistry and biochemical techniques
were carried out to address the question how increased
expression of PGRN, a documented protective molecule,
could be associated with pathology in AD. We employed a
series of human brain samples from non-demented cases
with low plaque and high plaque pathology, along with
samples from demented AD cases with high plaque and
tangle pathology to study the progression of changes of
PGRN and PSAP expression and their interactions. We
identified that PGRN and PSAP expression were increased
in AD cases, and their interaction could be demonstrated
in human brain samples. The interaction with PGRN and
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PSAP occurred early in plaque development being detect-
able in plaques present in the low plaque control cases,
and PGRN associated with Aβ plaques in all cases were
positive to differing extents for PSAP. Overall, these re-
sults suggest that the protective and inflammatory modu-
lating properties of PGRN might not be functional in AD,
and PSAP bound-aggregated PGRN associated with pla-
ques might lack the biological activities associated with
this protein. This can be the basis for further experimental
studies, but could be an important issue when considering
PGRN supplementation if the protein becomes seques-
tered into non-active or pathological forms associated
with plaques.
Materials and methods
Human brain samples
All human brain tissue samples used in this study were ob-
tained from the Banner Sun Health Research Institute Brain
and Body Donation Program (Sun City, Arizona, U.S.A.) as
part of the Arizona Study of Aging and Neurodegenerative
Diseases (AZSAND) [45]. The operations of the Brain and
Body Donation Program have received continuous approval
of different Institutional Review Boards (IRB). Current op-
erations have been reviewed by Western IRB (Puyallup,
WA, U.S.A.). Tissue studies carried out in the U.S.A. were
considered non-human subject research under exemption
4 (C.F.R 46.101). Tissue studies carried out in Japan were
approved by Shiga University of Medical Science Ethical
Committee (Certificate no. 29–114). A summary of demo-
graphic details of cases used in this study is presented in
Table 1. The details of cases used for immunohistochemis-
try are described in Table 1a, while those cases used for
protein analysis are described in Table 1b. The cases used
for protein analysis were all included in the larger group
used for immunohistochemistry.
Human brain autopsy and neuropathological diagnosis
At autopsy, brains were sectioned into 1 cm thick coronal
slices. Tissue taken from the right hemisphere of each brain
donor was frozen on dry ice, while coronal slices from the
left hemisphere were fixed for 2 days in 4% paraformalde-
hyde or 10% formalin, followed by cryoprotection in phos-
phate buffered glycol/glycerol solution. Frozen brain slices
were stored at − 70 to − 80 °C and retrieved for dissection
when samples were required for biochemical studies.
All donated brains received full neuropathological diag-
nosis including reference to pre-mortem clinical history of
each case. Consensus clinical and neuropathological cri-
teria were used to diagnose AD, Dementia with Lewy bod-
ies (DLB) or Parkinson’s disease (PD) in donated cases
[46, 47]. To assess severity of AD pathology in each case,
tissue sections from 5 brain regions (entorhinal cortex,
hippocampus, frontal cortex, temporal cortex and parietal
cortex) were stained with thioflavin-S, Gallyas and
Campbell-Switzer histological stains, and assessed semi-
quantitatively for the density of neurofibrillary tangles and
amyloid plaques. These methods of assessing pathological
load are carried out by the neuropathology department of
the Banner Sun Health Research Institute Brain and Body
donation program on each donated brain as part of diag-
nostic procedures. In brief, for each case, each brain re-
gion was ranked on a scale of 0–3 based on 0 being no
plaques or tangles, 1 being few plaques or tangles, 2 being
moderate numbers of plaques and tangles and 3 being nu-
merous plaques and tangles. By combining the measures
across these 5 brain regions, assessment of total AD path-
ology can be ranked on an ordinal scale of 0–15 for pla-
ques and tangles [48]. The cases were classified into low-
plaque non-demented (LP) (plaque score < 6), high-plaque
non-demented (HP) (plaque score 6–14) and AD with de-
mentia (plaque score > 12). The severity of Lewy body
pathology as a score of 0–40 was assessed in 10 different
brain regions using immunohistochemistry for phosphory-
lated alpha-synuclein according to the Unified Staging
Scheme for Lewy body disorders [49].
Apolipoprotein E genotyping
Apolipoprotein E genotypes were determined for most
cases using a polymerase chain reaction (PCR)/restriction
endonuclease fragment polymorphism method employing
Table 1 Demographic details of cases used in study
A. Demographic information of cases used for immunohistochemistry
Gender (M:F) Mean age ± SD PMI APOE4 Plaque score±SEM Tangle score±SEM BRAAK score
LP (n = 16) 8/8 84.75 ± 6.96 2.93 ± 0.88 0% (0/32) 2.54 ± 2.12 4.92 ± 2.33 I-IV
HP (n = 15) 7/8 85.62 ± 5.98 2.9 ± 0.64 10.7% (3/28) 10.49 ± 2.55 4.5 ± 1.93 II-IV
AD (n = 14) 6/8 80.64 ± 5.58 3.22 ± 0.98 35.7% (10/28) 13.33 ± 3.15 12.46 ± 3.95 V-VI
B. Demographic information of cases used for protein analysis
Gender (F/M) Mean age ± SD PMI APOE4 Plaque score Tangle score BRAAK score
LP (n = 12) 6/6 85.91 ± 8.93 3.09 ± 1.02 4.5% (1/22) 1.33 ± 1.93 5.43 ± 2.44 I-IV
HP (n = 9) 6/3 87.22 ± 8.22 2.72 ± 0.28 12.5% (2/16) 12.05 ± 1.58 5.38 ± 2.02 II-IV
AD (n = 11) 4/7 80.27 ± 3.82 3.79 ± 0.47 36.7% (8/22) 14.36 ± 0.67 13.5 ± 1.96 V-VI
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DNA extracted from cerebellum to discriminate between
APOE2, APOE3 and APOE4 alleles [50]. Results in Table
1 are presented as number of APOE4 alleles out of total
numbers of APOE alleles identified in each group.
Immunohistochemistry
Paraformaldehyde or formalin-fixed tissue sections from
temporal cortex (middle temporal gyrus) were used for
localization of progranulin (PGRN)-positive cells identified
with antibody AF2420 (R&D Systems, Minneapolis, MN,
U.S.A.), and for colocalization with Aβ peptide and phos-
phorylated tau, and markers of microglia (IBA-1, CD45),
astrocytes (GFAP), endothelial cells (CD31), lysosomal pro-
teins (LAMP-1, CD68, prosaposin, cathepsin D) and others
(sortilin, beta-secretase-1 (BACE1), TMEM106B, neurofila-
ments, synaptophysin) according to our previously pub-
lished procedures [51, 52]. Antibodies used in this study are
listed in Table 2. For this procedure, 25 μm brain sections
were processed using a free-floating method. Sections were
rinsed three times in phosphate-buffered saline containing
0.3% Triton-X100 (PBSTx) (0.1M Phosphate buffer, pH
7.4, 0.137M NaCl, 0.3% Triton-X100 (Nacalai-Tesque,
Kyoto, Japan)), and reacted in PBSTx containing 1% hydro-
gen peroxide (30min) to remove endogenous peroxidase
activity, rinsed three times in PBSTx and then incubated in
optimal dilutions of antibody overnight with shaking at
room temperature (RT). Sections were then rinsed three
times, incubated in biotinylated anti-species immunoglobu-
lin (Vector Laboratories, Burlingame, CA, U.S.A.) at 1:1000
for 2 h at room temperature, rinsed three times and then
incubated with avidin-biotin-peroxidase complex (ABC, 1:
1000, Vector Laboratories). Localization of bound antibody
was visualized using avidin-biotin horseradish peroxidase
(HRP) enzyme complex (ABC-Vector Laboratories)
histochemistry and nickel ammonium sulfate-enhanced
diaminobenzidine-HCl (100 μg/ml) (Dojindo, Kumamoto,
Japan) as substrate to produce a dark purple reaction prod-
uct. To detect a second antigen, reacted sections were
quenched in 1% hydrogen peroxide in PBSTx for 30min,
rinsed and then reacted with the second antibody in the
same manner. The second antibody was detected using
the same procedure, but with diaminobenzidine-HCl
(200 μg/ml) without nickel ammonium sulfate as sub-
strate to produce a brown reaction product. Sections
were then mounted on microscope slides, counter-
stained with neutral red, dehydrated and coverslipped
with permanent mounting agent.
Multi-color fluorescent confocal immunohistochemis-
try was carried out to verify cellular co-localization of
PGRN-expressing cells with certain other antigenic
markers, as described previously [51, 54]. Tissue sections
were incubated with optimal dilutions of antibodies at
room temperature overnight with shaking. After three
washes (10 min each) in PBSTx, sections were incubated
with optimal concentrations of fluorescent-labeled sec-
ondary antibodies. Bound primary antibodies were de-
tected with Alexa Fluor 488-donkey anti-goat IgG, Alexa
Fluor 568-donkey anti-rabbit or anti-mouse IgG or
Alexa Fluor 647-donkey anti-mouse IgG or anti-rabbit
IgG (all from ThermoFisher, U.S.A.). Sections were
counterstained with Sudan Black (1% solution in 70%
ethanol for 3 min) to quench tissue auto-fluorescence,
and with DAPI (ThermoFisher, U.S.A.) to reveal nuclei.
Sections were coverslipped with fluorescent mounting
media (Vector Laboratories) and imaged using an Olym-
pus FV1000 confocal microscope and system software.
Some images were acquired using a Leica SP8 confocal
microscope and this is indicated on the appropriate fig-
ure legend. All images presented are z-stacks of multiple
scans (5 scans). These were examined for saturation
using software. For imaging of plaques for fluorescent
intensity measurements and three-dimensional imaging,
z-stacks were acquired to encompass the entire structure
(15–20 scans with step-size of approximately 0.46 μm)
using the same laser settings.
Progranulin and Prosaposin antibody validation
To validate the specificity of the PGRN goat antibody
(R&D Systems #AF2420), antibody was incubated overnight
at 4 °C with recombinant human PGRN protein (R&D Sys-
tems #2420-PG, amino acids 18–593) in a mass ratio of 1:
200. Similarly, the PSAP rabbit antibody (R&D Systems
#AF8520) was incubated with recombinant human PSAP
protein (Sino-Biologicals, Beijing, China, #16224-H08H) in
the same ratio. Control and protein-absorbed antibodies
were diluted to the optimal concentrations for immunohis-
tochemistry and reacted with sections using the above-
described enzyme immunohistochemistry procedure.
PGRN-absorbed antibody prepared in the same manner
was also used for western blots.
Quantification of Progranulin-positive plaques
To quantify numbers and areas of PGRN-positive plaques,
brain sections double-stained for PGRN and Aβ by two-
color DAB enzyme histochemistry were used. Photomi-
crographs were taken with a 10x objective in 3-fields per
case. Images were enhanced to maximize color separation
between PGRN immunoreactivity (purple) and Aβ plaques
(brown). Field selection was performed by choosing 3
evenly-spaced fields encompassing all of the cortical grey
matter layers of each case. Images were imported to
Adobe Photoshop software (Adobe Inc., San Jose, CA,
U.S.A.) and a grid layer consisting of 90,000 pixels per area
(field) was created, and 10 fields were measured for a total
area of 900,000 pixels/case. The following measures for
each section were made; total number of plaques, number
of PGRN-associated-plaques, percentage area covered by
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PGRN-associated plaques and mean area of PGRN-
associated plaques as pixels/field.
Quantification of co-localization of Progranulin and
Prosaposin with Aβ plaques
The amounts of colocalization of PGRN- and PSAP-
immunoreactivity associated with Aβ plaques were quanti-
fied using double-stained confocal sections (PGRN and
PSAP) for 3 LP, 3 HP and 3AD cases. Sections were imaged
using an Olympus FV1000 confocal microscope. The set-
tings for laser intensities and number and thickness of scans
were determined based on optimal results for LP cases, and
these settings were maintained for all sections of HP and
AD cases. The images were analyzed using EzColocalization
plugin for ImageJ image analysis software [55, 56]. This was
used to determine the Pearson colocalization coefficient for
6 separate plaques analyzed for each case (total no. plaques
analyzed =18/disease group). Using the same images, the
fluorescent intensities of PGRN and PSAP and areas of
PGRN/PSAP plaques were also measured for each case.
Three-dimensional imaging and colocalization of PGRN
and Aβ interactions, and PGRN and PSAP interactions,
were carried out using Imaris 8 (Bitplane AG, Switzerland)
and Meshlab v2016_12 software (www.meshlab.net).
Western blotting
Extracts from brain samples were prepared by sonicating
each sample in 5-volumes of RIPA buffer (ThermoFisher
Table 2 Information of primary antibodies used for the study
Antigen Antibody Supplier Cat#. Species/Type Application Dilution
Progranulin PGRN R&D AF2420 Goat/Polyclonal IHC 1:4000
Systems FIHC 1:1500
WB 1:2000
IP 2 μg
Amyloid beta 6E10 Biolegend 803001 Mouse/Monoclonal IHC 1:2000
(1–16) FIHC 1:1000
WB 1:1000
CD45 CD45/HI30 Biolegend 304001 Mouse/Monoclonal IHC 1:2000
FIHC 1:1000
PHF-Tau (Ser202/Thr205) AT8 ThermoFisher MN1020 Mouse/Monoclonal IHC 1:2000
PHF-Tau AT180 Thermo MN1040 Mouse/Monoclonal FIHC 1:2000
(Thr231) Fisher WB 1:2000
IBA1 IBA1 Fujifilm 019–19,741 Rabbit/Polyclonal FIHC 1:1000
CD31 CD31 JC/70A Abcam Ab9498 Mouse/Monoclonal FIHC 1:500
GFAP GFAP BD bioscience 556330 Mouse/Monoclonal FIHC 1:1000
LAMP1 LAMP1 Sigma L1418 Rabbit/Polyclonal FIHC 1:1000
CD68 CD68 Biolegend 916104 Mouse/Monoclonal FIHC 1:1000
Prosaposin PSAP R&D AF8520 Rabbit/Polyclonal FIHC 1:2000
Systems WB 1:10000
IP 2 μg
Sortilin [53] Sortilin NT3 Abcam Ab16640 Rabbit/Polyclonal FIHC 1:1000
WB 1:2000
TMEM106B [34] TMEM106B Bethyl Lab A303- Rabbit/Polyclonal FIHC 1:1000
439A-1 WB 1:1000
Cathepsin D cathepsin D Cell signaling #2284 Rabbit/Polyclonal WB 1:1000
BACE1 BACE1 R&D MAB931 Mouse/Monoclonal FIHC 1:1000
Systems WB 1:2000
Pan NF SMI312 Biolegend 837904 Mouse/Monoclonal FIHC 1:1000
Synaptophysin SVP-38 Sigma S5768 Mouse/Monoclonal FIHC 1:500
goat IgG goat IgG R&D AB-108-C Goat/Polyclonal WB 1:2000
Systems IP 2 μg
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Scientific; 20 mM Tris-HCl, pH 7.5. 150mM NaCl, 1%
NP40, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate) supplemented with protease and phosphatase in-
hibitors (Nacalai-Tesque). These samples were used
without centrifugation for preparation of total protein
extracts for western blotting. A similar procedure was
used to extract proteins from cell pellets of THP-1-
derived macrophages and PGRN-overexpressing HEK-
293 cells. Total protein concentration of each sample
was determined using a MicroBCA assay kit with bovine
serum albumin as standard. For SDS gel electrophoresis
of brain protein samples, brain protein extracts (1 μg/ul)
were dissolved in 4xSDS gel sample buffer (Wako Che-
micals-FujiFilm, Japan) with or without reducing agent (0.1
M dithiothreitol), heated to 95 °C for 10min and loaded
onto 4–20% gradient pre-cast gels (Nacalai-Tesque, Kyoto,
Japan). Gel electrophoresis was carried out at 100 V in
Tris-glycine buffer except for Aβ proteins, which employed
Tris-tricine buffer (pH 8.5, 100mM Tris, 100mM tricine
and 0.1% SDS) as gel running buffer. Separated proteins
were transferred to nitrocellulose and processed for detec-
tion. Membranes were blocked in 5% skimmed milk dis-
solved in Tris-buffered saline with 0.1% Tween 20 (TBST –
20mM Tris-HCl, pH 7.6, 150mM NaCl, 0.1% Tween 20)
and incubated in optimal dilutions of antibody (see Table
2) in 2% milk in TBST overnight at room temperature.
Membranes were washed 3 times with TBST and incubated
2 h in HRP-labeled anti-goat, rabbit or mouse IgG (Ther-
moFisher) at 1:10,000. After a further 3 washes, membranes
were exposed to Chemi-Lumi One Super Chemilumines-
cent substrate (Nacalai-Tesque) and imaged using an Ima-
geQuant LAS 4000 system (GE LifeSciences, U.S.A.).
Images were adjusted and band intensities measured using
Image Studio Lite software (LI-COR, Lincoln, NE,
USA). After initial detection, all membranes (except
the immunoprecipitated samples) were reprobed with
an HRP-conjugated antibody to β-actin (Abcam, Cam-
bridge, MA. USA) for normalization purposes.
Paraformaldehyde fixation of Western blot membranes
Increased sensitivity and resolution of PGRN-
immunoreactive bands were obtained when western blot
membranes were fixed in paraformaldehyde (PFA)
vapor. A modification of the procedures described to in-
crease detection of α-synuclein was used [57–59]. Dried
membranes were exposed to vaporized PFA, rather than
by immersion fixation, in a sealed chamber at 60 °C for
30 min. After the PFA vapors had been vented, the
membranes were processed using the above-described
western blot detection method.
Enzymatic Deglycosylation
Enzymatic deglycosylation of PGRN was performed ac-
cording to the manufacturer’s protocol using PNGase F
(New England Biolabs, Beverley, MA, U.S.A.) [54].
Twenty μg of protein lysates from cells and brain sam-
ples were diluted in denaturation buffer and heated at
100 °C for 10 min. PNGase F enzyme (1 unit) was added
to those samples along with enzyme buffers and NP-40.
Following incubation of 1 h at 37 °C, samples were di-
luted in 4xSDS sample buffer and analyzed by the de-
scribed SDS-PAGE/western blot method.
Co-Immunoprecipitation
RIPA-brain extracts prepared for western blots were
centrifuged at 14,000 g/30 min to prepare samples for
immunoprecipitation assays. Immunoprecipitations were
carried out using protein G- or protein A-coupled mag-
netic beads (G-Biosciences, St. Louis, MO, U.S.A.) con-
jugated with test antibodies. For each sample, 10 μl of
Protein G or Protein A magnetic beads were collected
and washed with PBS 0.01% Tween 20 (PBST) using a
magnetic stand, which were then mixed with 2 μg of
antibody (PGRN goat polyclonal, PSAP rabbit poly-
clonal, or normal goat IgG) for 30 min with constant
mixing. Unbound antibodies were removed by washing
beads with PBST, then 200 μg of brain protein extract or
100 μg of cell protein extracts were added to the
antibody-coupled beads. Samples were mixed with
antibody-conjugated beads for 18 h at 4 °C with rotation,
washed three times with RIPA, and then eluted into SDS
sample buffer without reducing agent at 80 °C. The
omission of reducing agent and lower denaturation
temperature prevented the eluted immunoglobulin mol-
ecules from being denatured to molecular sizes that
interfere with detection of target proteins. Samples were
separated through SDS polyacrylamide gels and trans-
ferred to nitrocellulose membranes as described and de-
tected with different antibodies by western blot.
Progranulin-expressing cell culture
Protein extracts from macrophage-like cells produced
from the THP-1 monocytic cell line and neuronal cells
produced from LAN-5 neuroblastoma cells were used
PGRN-containing samples for antibody validation stud-
ies,. THP-1 monocytes (TIB-202) obtained from the
American Type Culture Collection (Manassas, VA,
U.S.A.), were cultivated in suspension culture using
RPMI media (Nacalai-Tesque) supplemented with 10%
fetal bovine serum (FBS), and differentiated into adher-
ent macrophage-like cells by treatment with 25 nM
phorbol myristate acetate (PMA – Sigma Aldrich, St.
Louis, MO, U.S.A.) for 3 days in RPMI with 5% FBS.
LAN-5 neuroblastoma cells (provided by Dr. R.C. See-
ger, Children’s Hospital of Los Angeles, CA, U.S.A.)
were used as a human neuronal model [60]. Cells were
cultured in RPMI with 10% FBS and differentiated in
RPMI with 5% FBS containing 10 μM retinoic acid
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(Nacalai-Tesque). A PGRN-overexpressing stable-
transfected HEK cell line was also prepared. HEK cells
were transfected with plasmid expressing PGRN protein
fused with a green fluorescent protein sequence (gift
from Dr. Morimura, Shiga University of Medical Science,
Japan) and selected for resistance to G418 (500 μg/ml).
Cells were collected and analyzed by western blot or im-
munoprecipitation for expression of PGRN.
Data analysis
Western blot data and plaque measurement data were an-
alyzed by one-way Analysis of Variance (ANOVA) with
Newman-Keuls post-hoc test for significance between
paired groups. Significant differences were assumed if P
values of less than 0.05 were obtained. All statistical ana-
lyses were carried out using Graphpad Prism Version 7
software (Graphpad software, La Jolla, CA, U.S.A.).
Results
Progranulin (PGRN) immunoreactivity in AD pathological
structures
Initial analysis of PGRN expression in relation to patho-
logical structures in human middle temporal gyrus (MTG)
were carried out using dual-color enzyme immunohisto-
chemistry on free-floating (25 μm) sections. The complete
series of low plaque non-demented (n = 16), high plaque
non-demented (n = 15) and AD cases (n = 14) were
stained for PGRN in combination with 6E10, an antibody
that detected Aβ, and PGRN in combination with CD45, a
marker to identify microglia. Figure 1-panels A-C show
representative images of the morphologies of PGRN-
associated with Aβ plaques. In low plaque (low pathology)
non-demented cases, it was observed that although plaque
numbers were sparse, many were PGRN-positive (Fig. 1a).
The size and number of PGRN-associated plaques in-
creased in the high plaque and AD cases (Fig. 1b, Fig. 1c).
It was hypothesized that PGRN immunoreactivity
around plaques would be due to its expression by infiltrat-
ing microglia. PGRN/CD45 stained sections revealed that
most microglia were positive for PGRN, but this was more
intense in reactive microglia in AD cases (Fig. 1d-f).
PGRN immunoreactivity was also detected in neurons in
these sections. These could be clearly identified by their
morphology (Fig. 1d-f, insets a). The morphology of indi-
vidual microglia are shown as insets b in Fig. 1d-f. Figure
1 panels G-I show that PGRN-immunoreactive plaque
structures are infiltrated by microglia in each of the dis-
ease groups, but much of this PGRN immunoreactivity
was not associated with microglia. Selected sections from
these staged plaque series with low, medium and abun-
dant numbers of tangles (Table 1) were also stained for
PGRN and phosphorylated tau (p-tau). Two separate p-
tau antibodies were used; AT8, which is specific for tau
phosphorylated at serine 202 and threonine 205, and
AT180, which is specific for p-tau at threonine 235. Figure
1 (panels J-L) show that AT8 immunoreactive tangles
were not positive for PGRN, and similarly, using confocal
microscopy AT180 immunoreactive structures were not
positive for PGRN (Fig. 1, panels M-O).
Progranulin is expressed in neurons, microglia and blood
vessels but not astrocytes in human middle temporal
gyrus
To confirm colocalization features at the cellular level,
multi-color confocal fluorescent microscopy was carried
out on selected cases from each group. Colocalization of
PGRN in microglia was confirmed by confocal micros-
copy with microglia being identified using an antibody
to IBA-1 (Fig. 2, panels A - C). A feature of PGRN im-
munoreactivity that can be seen in Fig. 2 (panels A and
C) is PGRN immunoreactive structures in microglia (ar-
rows) are larger than those in neurons (arrowheads). We
had also observed vascular staining for PGRN in enzyme
histochemistry-stained sections, but using confocal mi-
croscopy, we could not confirm that immunoreactivity
colocalized with CD31, a specific marker for endothelial
cells (Fig. 2f, arrowheads). PGRN staining was present in
many vessels with staining possibly being in the extracel-
lular basement membrane surrounding the vessels (Fig.
2, panels D-F). Staining of PGRN in brain vasculature
has not previously been reported. PGRN immunoreactiv-
ity did not colocalize with GFAP-positive astrocytes in
any of the sections examined (examples; Fig. 2, panels
G-I). We also further examined the interaction of IBA-
1-positive microglia with PGRN in low plaque, high
plaque and AD cases (Fig. 2, panels J-L). Most plaque-
infiltrating microglia showed some colocalization with
PGRN (yellow, indicated by arrows), but these figures
show that most plaque-associated PGRN did not colo-
calize with microglia (arrowheads).
Validation of progranulin antibody used for
immunohistochemistry
Due to concerns raised about the specificity of commer-
cial antibodies to PGRN and granulin (GRN) [61], valid-
ation studies were carried out with the PGRN antibody
(AF2420; goat polyclonal, R&D Systems, Minneapolis,
MN, U.S.A.) used in this study. This antibody has
unique features having being prepared against a glycosyl-
ated recombinant fragment consisting of the majority of
the PGRN protein (amino acids 18–593). Immunization
with this peptide will have produced an antibody specific
against many different epitopes encompassing the
complete PGRN protein rather than a single epitope.
Immunohistochemistry was carried out with MTG tis-
sue sections using PGRN antibody that had been
absorbed with PGRN-immunizing peptide or control-
absorbed. Sections were developed for single-color
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enzyme immunohistochemistry with counterstaining.
Additional file 1: Figure S1 illustrates results from one of
the AD sections examined showing that immunohisto-
chemistry with absorbed antibody resulted in absence of
cellular and plaque staining (Additional file 1: Figure
S1A compared to Figure S1B).
Further characterization of the PGRN antibody was
carried out by western blot using protein extracts of
Fig. 1 Progranulin Interactions with AD pathological Features. (a-c). Representative photomicrographs of progranulin (PGRN)(purple)
immunoreactivity associated with amyloid beta (Aβ) plaques (brown) in MTG sections of low plaque, high plaque and Alzheimer’s disease cases.
Scale bar represents 30 μm. (d-f). Photomicrographs of PGRN (purple) immunoreactivity associated with CD45 immunoreactive microglia in MTG
sections of low plaque (d), high plaque (e), and Alzheimer’s disease cases (f). Insets a) show at higher magnification PGRN-positive stained
neurons present in each section. Neurons are identified by their size and characteristic shape. Insets b) show higher magnification of PGRN-
positive microglia. Scale bar represents 20 μm (d-f), and 10 μm for insets. (g-i). Photomicrographs of PGRN (purple) with plaque-associated CD45-
positive microglia (brown). Progressive increase in accumulation of CD45-positive microglia in low plaque (g), high plaque (h) and Alzheimer’s
disease (i) cases. Scale bar represents 30 μm. (j-o). Absence of PGRN immunoreactivity of neurofibrillary tangles. (j-i) Photomicrographs of PGRN
(purple) and phosphorylated tau (AT8)(brown) double-stained sections from low plaque (j), high-plaque (k), and Alzheimer’s disease cases (l). (m-
o). Confocal micrographs of PGRN (green) and phosphorylated tau (AT180)-positive tangles in low-plaque (m), high-plaque (n) and Alzheimer’s
disease (o) cases. Scale bar represents 10 μm.
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MTG brain samples and PGRN-expressing cells. This
antibody detected major polypeptide band(s) of approxi-
mately 75–80 kDa, which corresponds to full-length gly-
cosylated PGRN, and also a minor polypeptide band of
55 kDa. In samples with high levels of PGRN expression,
higher molecular immunoreactive bands can also be
detected (Additional file 2: Figure S2A and Figure S2B)
suggestive of dimers. Western blots showed that the
PGRN polypeptide bands were absent in blots probed
with peptide-absorbed (+ Peptide) antibody compared to
unabsorbed (−Peptide) antibody (Additional file 2: Fig-
ure S2A). Optimization studies for the detection of
Fig. 2 Confocal Immunohistochemistry of progranulin with cellular markers. (a-c). Cellular expression of PGRN (green) (a), microglial marker IBA-1
(red) (b) and colocalization of structures within microglia (yellow) (c) in a high plaque case. Green immunoreactivity that did not colocalize with
IBA-1 (red) immunoreactivity identified cells with neuronal morphology. Scale bar represents 20 μm. (d-f). PGRN immunoreactivity (green) (white
arrowheads) was present within cerebral vessels, but did not colocalize with the endothelial marker CD31 (red) in AD case. Scale bar represents
20 μm. (g-i). PGRN immunoreactivity (green) (g) did not colocalize with astrocyte marker GFAP (red) (I). Scale bar represents 20 μm. (j-l).
Expression of PGRN (green) and microglial marker IBA-1 (red) associated with plaque structures of low plaque (J), high plaque (k), and Alzheimer’s
disease (l). PGRN-positive microglia (yellow – arrows) are observed in microglia clustering and infiltrating PGRN- positive plaque-associated
structures. Most of the PGRN immunoreactivity (arrowheads) appeared separate from DAPI-stained nuclei (DAPI – blue). Scale bar
represents 30 μm.
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PGRN polypeptides by western blot showed that omis-
sion of reducing agents in brain and control cellular
samples significantly enhanced the sensitivity of detec-
tion of PGRN polypeptides (Additional file 2: Figure
S2B). This was particularly noticeable in extracts of
THP-1 macrophage-like cells and LAN-5 neuronal-like
cells (Additional file 2: Figure S2B, comparing between +
DTT and – DTT lanes). Furthermore, fixation of west-
ern blot membranes with paraformaldehyde (PFA) vapor
also increased the resolution and sensitivity of the de-
tected PGRN bands in brain samples. The major poly-
peptide band(s) of 75–80 kDa could be resolved into two
separate bands on the PFA-treated membranes (Add-
itional file 2: Figure. S2C). This pretreatment allowed
better detection of the 55 kDa band that could be diffi-
cult to detect in brain samples of non-PFA treated mem-
branes. Subsequent western blot analyses incorporated
these technical changes (Fig. 6 and Additional file 3: Fig-
ure S3). To show that the 75–80 kDa bands were glyco-
sylated and the 55 kDa band represented unglycosylated
PGRN, brain samples and THP cell extracts were treated
with the deglycosylation enzyme PNGaseF and analyzed
by western blot (Additional file 2: Figure S2D). The shift
from 75 kDa to 55 kDa was evident in only one of two
bands in the PNGaseF-treated samples, but increased
levels of 55 kDa in these brain samples can be clearly
seen. In the treated THP cell extract, the shift in mo-
lecular weight was complete (THP+ compared to THP-
sample) (Additional file 2: Figure S2D).). These findings
verified that the goat PGRN antibody specifically identi-
fied PGRN in tissue and in protein extracts. An import-
ant feature to observe in Additional file 3: Figure S3A).,
which shows the complete membranes used for mea-
surements of PGRN in brain samples, is the absence of
low-molecular weight granulin peptides.
Characterization of progranulin immunoreactive
structures associated with plaques in staged MTG cases
It was observed that many of the Aβ plaques present in
all cases studied had PGRN-immunoreactive structures,
even the few plaques present in many of the low plaque
cases. This indicated that PGRN association with Aβ
plaques was an early pathological event. The distribution
of PGRN and Aβ immunoreactivity across cortical layers
is shown at low magnification in representative images
of low plaque (Fig. 3a), high plaque (Fig. 3b), and Alzhei-
mer’s disease (Fig. 3c) cases. Inset images represent
PGRN-positive and negative plaques in each group.
Examples of PGRN-negative and positive plaques are
also shown at higher magnification (Fig. 3d). The nega-
tive plaques appeared to have a more diffuse morph-
ology than positive plaques. This was characterized by
staining selected sections with thioflavin-S (thio-S) to
identify aggregated plaques. PGRN immunoreactivity
was associated with thio-S positive, Aβ positive plaques
but not thio-S negative, Aβ positive plaques (Fig. 3e).
Seven of the 15 LP cases had no detectable Aβ plaques
in the MTG sections examined, while in the remaining
LP cases with Aβ plaques, many of these were PGRN-
positive. The numbers of Aβ plaques (Fig. 3f) and the
number of PGRN-associated Aβ plaques (Fig. 3g) were
calculated in sections from each case. This measure did
not account for the size or intensity of PGRN immuno-
reactivity in plaques only its presence or absence. We
used these images to calculate the percentage area occu-
pied by PGRN-associated Aβ plaques for each case (Fig.
3h), and the mean area of positive plaques (Fig. 3i). Al-
though there were significantly more PGRN-positive pla-
ques with significantly larger total areas in the AD cases
compared to the HP cases, we noticed differences in the
morphologies of PGRN-associated Aβ plaques between
HP and AD cases. Many of the PGRN-positive Aβ pla-
ques in AD cases had less intense coverage of PGRN im-
munoreactivity (top insets Fig. 3b and c). This was
investigated further in subsequent sections.
Further detailed studies of PGRN interactions with Aβ
plaques were also carried out by confocal microscopy
(Fig. 4). Thioflavin-S histochemistry combined with
PGRN and Aβ immunohistochemistry was used to show
that mature aggregated thio-S positive plaques in Alzhei-
mer’s disease cases showed some associated PGRN im-
munoreactive structures, while thio-S positive tangles
did not (Fig. 4 (a-d), low magnification and Fig. 4 (e-h)
higher magnification). Figure 4d (arrowhead) did identify
a dense-cored, burnt-out plaque that was thio-S positive
but had minimally detectable associated PGRN. The fea-
tures of PGRN-positive plaques in low plaque, high
plaque and Alzheimer’s disease cases revealed that most
of the deposits of PGRN around plaques appeared extra-
cellular, and even though cell membranes are not visible
in the sections, most PGRN immunoreactivity was not
clearly associated with nucleated cells (Fig. 4 panels L, P,
T). Comparison of plaque morphologies between cases
showed the relative size and distribution of PGRN in
plaques varied between groups. In the low plaque and
high plaque cases, the PGRN appeared as aggregates
around the developing plaque with some colocalization
with Aβ (Fig. 4 Merged – yellow arrows Fig. 4k and l
compared to Fig. 4o and p). In the AD cases, there was
less colocalization, and the Aβ immunoreactivity (Fig. 4s
and i) extended beyond the PGRN-positive structures.
This feature can also be seen in Fig. 4h).
The confocal images of PGRN and Aβ-stained plaques
were further analyzed using computer-assisted three-
dimensional imaging. These images showed the inter-
action of PGRN and Aβ positive structures in the AD
case shown in Fig. 4t. Figure 4u shows a computer ren-
dered three-dimensional image of the highlighted area
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indicated in Fig. 4t. Analysis of the 3-D rendered image
with MeshLab software in Top view (Fig. 4v) and Side
view (Fig. 4w), which analyzed the interactions through
multiple layers, showed some overlap of these structures
(Fig. 4v and Fig. 4w – yellow overlap) but most of the
structures appeared separate (green: PGRN, red: Aβ).
Overall, the arrangements appeared to confirm the im-
ages from enzyme and confocal microscopy of the pres-
ence of two aggregated structures associated with each
other but with limited colocalization. Similar interaction
mesh images could be produced from confocal images
of PGRN associated with plaques from low plaque and
high plaque cases.
Analysis of interactions of PGRN-immunoreactive
structures with neuritic plaques were carried out using
markers for pTau (antibody AT180), pan-neurofilaments
(preferentially phosphorylated neurofilaments) (antibody
SMI312) and synaptophysin. Images from Alzheimer’s dis-
ease case are shown (Additional file 3: Figure S3 Add-
itional file 3: Figure S3). Each of these markers identify
distinct neuronal components. Each neuritic plaque
shown (Additional file 3: Figure S3A, D, G) showed strong
associated PGRN staining. The merged images showed lit-
tle to no colocalization of these neuronal markers and
PGRN on the neuritic plaques observed (Additional file 3:
Figure S3C-pTau; Additional file 3: Figure S3F-NF; Add-
itional file 3: Figure S3I-synapto). This was assessed by the
absence of yellow colocalization in the Z-stack images.
Association of Progranulin with lysosomal proteins
A study of PGRN and lysosomal proteins on plaques of
5xFAD AD-model transgenic mice had observed that most
Aβ plaques colocalized with lysosomal proteins, and that
most PGRN associated with Aβ plaques colocalized with
lysosomal-associated membrane protein-1 (LAMP-1) [32].
These authors hypothesized that PGRN associated with
plaques represented an aberrant accumulation in
lysosomes. We carried out confocal microscopy with anti-
bodies to lysosomal proteins LAMP-1 and CD68 in con-
junction with PGRN to verify whether these observations
could be made in human brain materials. Figure 5(I) shows
representative results for PGRN and LAMP-1. The anti-
body to LAMP-1 used in this study only identified neurons
and not microglia. Figure 5 (I) (panels A-C) demonstrated
that PGRN immunoreactivity almost completely coloca-
lized with LAMP-1 in neurons. This verified the specificity
of LAMP-1 immunoreactivity to lysosomal structures.
Examining PGRN-positive plaques in sections from low
plaque (Fig. 5 (I) (panels D-F), high plaque (Fig. 5 (I)
(panels G-I), and Alzheimer’s disease sections (Fig. 5 (I)
(panels J-L) identified different amounts of LAMP-1 stain-
ing, but limited colocalization of PGRN with LAMP-1 in
these plaque structures was evident. There were greater
amounts of colocalization in the low plaque and high
plaque cases than in the AD cases (Fig. 5 (I) (panels F, I, L)
(yellow – indicated by arrows).
CD68, a macrophage-specific lysosomal membrane
protein, was used to identify colocalization of PGRN in
lysosomes of microglia. Figure 5 (II) (panels A-C) show
almost complete colocalization of PGRN and CD68 in
isolated microglia on an AD section (yellow – indicated
by arrows). Examining plaque structures showed that in
low plaque cases, CD68 showed significant colocalization
with PGRN (Fig. 5 (II) (panel F). In high plaque and AD
cases, with larger plaques, there was still extensive colo-
calization (yellow-indicated by arrows), but much of the
PGRN immunoreactivity did not colocalize with CD68,
and appeared not to be cell-associated (green-indicated
by arrowheads).
Progranulin protein levels in low plaque, high plaque and
AD MTG samples
Measurement of PGRN protein levels in LP, HP and AD
samples were carried out using the described technical
(See figure on previous page.)
Fig. 3 Quantification of numbers and areas of progranulin-positive plaques. (a-c). Low magnification of representative images of low plaque (a), high
plaque (b) and Alzheimer’s disease (c) cases stained for PGRN (purple) and Aβ (6E10) brown. Series of sections were used for quantification using
image analysis software. Examples of PGRN-positive (top) and PGRN-negative plaques (lower) are shown as insets. Scale bars represent 200 μm. (d).
Higher magnification images of PGRN-negative (arrowhead) and PGRN-positive (arrows) amyloid plaques identified with antibodies to PGRN (purple)
and 6E10 (brown). PGRN-positive plaques tended to have a more aggregated morphology while PGRN-negative were more diffuse. Scale bar
represents 30 μm. (e). PGRN, Aβ and thioflavin-S confocal microscope image. Colocalization of PGRN (red) associated with thioS-positive (green)-Aβ
plaques (blue)(arrows) with thioS-negative Aβ plaque with minimal amount of PGRN (arrowhead) in an AD section. Scale bar represents 20 μm. Images
were acquired with Leica SP8 microscope. (F). Bar chart showing total number of Aβ plaques in all cases studies. LP (n = 16), HP (n = 15) and AD (n =
14). Results represent mean ± standard error of mean (S.E.M.). Significant increase in numbers of plaques in HP and AD compared to LP **** (p <
0.0001), between LP and HP **** (p < 0.0001) and between HP and AD (** p < 0.01). (G). Bar chart showing number of Aβ plaques with associated
PGRN in all cases studies. LP (n = 16), HP (n = 15) and AD (n = 14). Results represent mean± standard error of mean (S.E.M.). Significant increase in
numbers of plaques in HP and AD compared to LP **** (p < 0.0001) and between HP and AD (**** p < 0.0001). (h). Bar chart showing total area
(percentage) occupied by PGRN-associated Aβ plaques in all cases studies. LP (n = 16), HP (n = 15) and AD (n = 14). Results represent mean ± S.E.M.
Significant increase in numbers of plaque occupied area in HP and AD compared to LP **** (p < 0.0001) and between HP and AD (**** p < 0.0001). (i).
Bar chart showing average plaque size (pixels) of PGRN-associated plaques in all cases studies. Numbers derived from total area occupied divided by
number of plaques for each case. Results represent mean ±S.E.M. LP (n = 16), HP (n = 15) and AD (n = 14). Significant increase in average plaque size in
LP and AD compared to LP ****p < 0.001) and between HP and LP (*** p < 0.001). NS - Not significantly different.
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Fig. 4 Characterization of progranulin immunoreactivity associated with different types of Aβ plaques in low plaque, high plaque and Alzheimer’s
disease cases (a-d). Thioflavin-S staining of Alzheimer’s disease tissue section (low magnification) characterization of PGRN (red) and Aβ-
immunoreactive plaques (blue). Triple-color merged image (D) identifies that thio-S plaques have PGRN-positive associated structures but thio-S
positive tangles show no PGRN immunoreactivity. Box area in D illustrates areas shown at higher magnification in panels E-H. Scale bar represents
100 μm. (e-h). Higher magnification of area from D showing thio-S positive plaques and tangles (green), PGRN (red) and Aβ (blue). Scale
represents 25 μm. Images were acquired with Leica SP8 microscope. (i-l). Low Plaque case: Features of PGRN (green) immunoreactive
accumulations (I) around Aβ (red) immunoreactive plaque (j), and merged images (k and l) showing limited overlap (yellow) between PGRN and
Aβ. Image D with DAPI-stained nuclei demonstrate the presence of cells around the plaque. (m-p). High Plaque case: PGRN (green)(M) and Aβ
(red)(N) immunoreactivity showing more extensive colocalization (yellow) (O and P). (q-t). Alzheimer’s disease case: PGRN (green) (q)
immunoreactivity and Aβ (red) (R) show less colocalization (yellow) with the formation of larger AD plaques. PGRN aggregates are present within
the Aβ immunoreactive areas but with limited colocalization (Q and T). Three-Dimensional Reconstructions of progranulin-positive Aβ plaques. (u-
w). Three-dimensional reconstruction and Mesh rendering of PGRN and Aβ immunoreactive plaques in AD case (U). Mesh rendering of three-
dimensional modelled plaque shown in panel (Top view, panel V). The two immunoreactive structures (PGRN-green; Aβ-red) are present as
aggregates but show limited areas of interaction (Side view, panel W). Similar patterns of colocalization were observed for LP and HP cases.
Fig. 5 Association of progranulin with lysosomal proteins. i) Progranulin and Lysosomal-Associated Membrane Protein-1 (LAMP-1) interactions in
neurons and plaques. (a-c). PGRN (green) (A) and LAMP-1 (red) (b) immunoreactivity in neurons show almost complete colocalization (yellow), (c)
showing PGRN in neurons is mainly localized to lysosomes. Scale bar represents 10 μm. (d-f). PGRN immunoreactivity (green) (d) and LAMP-1
(red) (E) in plaques of low plaque case showed limited colocalization (arrows-yellow) (F). Scale bar represents 30 μm. (g-i). PGRN immunoreactivity
in plaques (green) (G) and LAMP-1 (red) (H) in plaques of high plaque case showed more extensive colocalization (arrows-yellow) (I). Scale bar
represents 30 μm. (j-l). Limited immunoreactivity for LAMP-1 in AD cases (k). PGRN immunoreactivity in plaques (green) (j) and LAMP-1 (red) (k) in
plaques of AD case showed very limited colocalization (arrows-yellow) (l). Scale bar represents 30 μm. II) Progranulin and lysosomal protein CD68
interactions in microglia and plaques. a-c). PGRN (green) (a) and CD68 (red) (b) immunoreactivities in microglia show almost complete
colocalization (yellow) (c) showing PGRN in microglia is mainly localized to lysosomes. Plaque-associated CD68 and PGRN show almost complete
colocalization Scale bar represents 10 μm. (d-f). Low plaque case: (g-i). High plaque case: (j-l). Alzheimer’s disease case. CD68 (red) and PGRN
immunoreactivity (green) showed extensive colocalization (arrows-yellow) in all groups but most plaque-associated PGRN did not colocalize
(green). Scale bar represents 30 μm.
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modifications (omission of reducing agents and parafor-
maldehyde fixation of membranes) to improve sensitivity
of detection of PGRN-related polypeptides. Measure-
ments of total PGRN levels were determined that com-
bined the intensities of the major 75–80 kDa bands and
minor 55 kDa band (representative blot Fig. 6d; complete
series of blots Additional file 4: Figure S4A). There were
significantly increased levels of PGRN in AD cases com-
pared to HP and LP cases, but not between HP and LP
cases (Fig. 6a). This indicated the overall increase in
PGRN occurred later in the disease. These blots were
also analyzed for levels of Aβ (Fig. 6b)–Aβ, and
Fig. 6 Biochemical analyses of Progranulin in MTG samples compared to Aβ and phosphorylated tau. a). Scatter plot showing expression levels of
PGRN protein in the different groups. Results presented represent the combination of levels of 75–80 kDa and lower molecular weight (55 kDa) PGRN
protein bands. Results represent mean ±S.E.M. Significantly increased levels of PGRN protein were present in AD case compared to LP and HP cases
but not between LP and HP cases (** p < 0.01, ns – not significant). b). Scatter plot showing expression levels of Aβ protein in the different groups.
Results presented represent the levels of all p-tau detected bands. Results represent mean ±S.E.M. Significantly increased levels of Aβ (monomer)
protein were present in AD case compared to LP and AD cases but not between LP and HP or HP and AD cases (** p < 0.01, ns – not significant).
Outlier HP case indicated by red arrow (see text). c). Scatter plot showing expression levels of phosphorylated tau (p-tau – Thr 231) protein in the
different disease groups. Results presented represent the levels of all p-tau detected bands. Results represent mean ±S.E.M. Significantly increased
levels of p-tau protein were present in AD cases compared to LP and HP cases but not between LP and HP cases (* p < 0.05, ** p < 0.01, ns – not
significant). d). Western blots showing bands detected with goat antibody to PGRN (PGRN) in MTG protein extracts from low plaque (LP), high plaque
(HP) and AD cases. The complete series of samples are presented in Additional file 4: Fig. S4A). The same blots were reprobed with antibody AT180 to
phosphorylated tau (pTau), and β-actin for normalization purposes. e). Western blots showing bands detected with antibody 6E10 to Aβ in MTG
protein extracts from low plaque (LP), high plaque (HP) and AD cases. Results represent mean ±S.E.M. Samples were separate from those in panel A by
using Tris-tricine gels to resolve low molecular weight bands. f). Correlation Analyses between PGRN protein and Aβ protein levels for all samples.
Significant correlation (r = 0.5422, p = 0.0013). g). Correlation Analyses between PGRN protein and p-tau (Thr231) protein levels for all samples.
Significant correlation (r = 0.5264, p = 0.002).
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phosphorylated tau (p-tau-Thr231)(Fig. 6c)-pTau). Re-
sults showed significantly greater Aβ in AD cases but
not compared to HP cases. However, the Aβ level in one
HP case (indicated with a red arrow (Fig. 6b) was much
higher than the remainder of the HP samples. This sam-
ple was from a 99 year-old subject with a plaque score of
14 but without documented dementia. This case had
high PGRN levels and was identified as a statistical out-
lier. Removing it from the analysis of Aβ levels between
groups produced significant difference between HP and
AD (p < 0.01); this case was included in the correlation
analyses (Fig. 6f). Correlation analyses between PGRN
and Aβ levels (Fig. 6f) showed statistical significance
(Pearson r = 0.5422, p = 0.0013). We also compared
PGRN expression levels with p-tau (Thr231) (Fig. 6d-
pTau). Although there was no evidence of p-tau and
PGRN colocalization at the cellular level, there was sig-
nificant correlation between PGRN and p-tau (AT180)
levels (Pearson r = 0.5264, p = 0.0020) (Fig. 6g). These
results indicate total PGRN levels increased with in-
creasing amounts of plaque and tangle pathology.
Co-immunoprecipitation of Progranulin-binding proteins
in brain samples identified prosaposin
We used co-immunoprecipitation/western blot method-
ology involving precipitation of PGRN from human
brain samples with PGRN-antibody conjugated magnetic
beads followed by western blot with antibodies to certain
previously identified PGRN-interacting proteins. Control
experiments identified that immunoprecipitation of
PGRN using brain samples and PGRN-overexpressing
HEK cells pulled-down prosaposin (PSAP) (Fig. 7a
-PGRN). This interaction was confirmed by showing im-
munoprecipitation of PSAP pulled-down PGRN (Fig. 7a
-PSAP). The samples were eluted from the beads under
non-reducing conditions and analyzed by western blot
for other possible proteins interacting with PGRN. Elu-
tion of proteins under non-reducing conditions at 80 °C
(instead of 95 °C) resulted in samples with limited inter-
ference with dissociated immunoglobulin polypeptides.
Under the immunoprecipitation conditions used, we
only detected PSAP by western blot in brain samples
precipitated with PGRN antibody-conjugated magnetic
beads. These samples were also probed with antibodies
to sortilin, TMEM106B, cathepsin D and beta-secretase-
1 (BACE-1) but did not detect these proteins (Additional
file 5: Figure S5A and S5B). However, sortilin, cathepsin
D and BACE-1 were detected in brain samples precipi-
tated with PSAP (Additional file 5: Figure S5A and S5B).
The lack of colocalization of these proteins with PGRN
on plaques was confirmed by confocal microscopy on
AD sections (Additional file 5: Figure S5, panels D-O). A
larger series of LP, HP and AD brain MTG extracts were
analyzed for the interaction of PGRN and PSAP.
Samples were immunoprecipitated with PGRN antibody
and analyzed for PSAP by western blot (Fig. 7b). Match-
ing blots were probed with PGRN antibody to confirm
its precipitation. Quantification of band intensities and
calculation of ratio of intensities of PSAP to PGRN
showed no significant differences between the different
groups of samples (Additional file 5: Figure S5C). Images
of the full blots for immunoprecipitation experiments
confirm the absence of saposin peptides (Additional file
6: Figure S6A) and granulin peptides (Additional file 6:
Figure S6B) interacting with brain samples precipitated
with antibody to PGRN. Samples from HEK cells over-
expressing PGRN (Additional file 6: Figure S6C- lanes IP
PGRN +, HEK) precipitated with PGRN antibody did
show some granulin reactive bands in the blot after
longer exposure.
To follow up the identification of PSAP as a PGRN-
binding protein in brain, quantification of PSAP protein
levels was carried out in the same complete series of
MTG brain samples used for PGRN western blot ana-
lysis. These samples were also analyzed in the absence of
reducing agents with proteins on transferred membranes
being fixed with PFA vapors, as described for PGRN
analyses. These analyses showed a significant increase in
AD compared to LP (p < 0.01) and HP (p < 0.05) cases
(Fig. 7d), but not between LP and HP cases. Figure 7c is
a representative western blot image of PSAP in brain
samples with the complete series of blots shown in Add-
itional file 3: Figure S3B. As expected, there was signifi-
cant correlation between PGRN and PSAP levels in
these brain samples (Fig. 7e - Pearson r = 0.4674, p =
0.0070). In addition there was significant correlation be-
tween PSAP and Aβ levels (Fig. 7f - Pearson r = 0.4583,
p = 0.0083).
Immunohistochemical colocalization of prosaposin with
progranulin and cellular markers
We have shown using co-immunoprecipitation methods
that PGRN and PSAP are interacting in brain protein ex-
tracts. This led to the question whether there were inter-
actions of these molecules around plaques in our
human brain samples. Experimental studies have shown
that the interactions of PGRN and PSAP have signifi-
cant effects on their cellular trafficking and biochemical
properties [40, 42].
We confirmed the specificity of the PSAP by peptide
absorption. Sections reacted with PSAP-absorbed anti-
body did not show immunoreactivity (Additional file 1:
Figure. S1C) compared to control-absorbed antibody
(Additional file 1: Figure. S1D). In AD cases, PSAP im-
munoreactivity was present in most neurons. This is evi-
dent in most panels of Fig. 8. PSAP was also associated
with many Aβ plaques, but the two molecules seemed to
show limited interactions as evidenced by the red
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immunoreactivity (PSAP) on the plaque and limited
amounts of colocalized yellow (PSAP + Aβ) (arrows Fig.
8c)(Fig. 8a-c). Triple staining for PGRN, PSAP and Aβ
of plaques in AD cases showed similar morphologies
around Aβ-positive structures (Fig. 8d and e). There was
extensive though not exclusive colocalization of PGRN
and PSAP associated with Aβ-immunoreactive struc-
tures (Fig. 8f). As some PGRN staining around plaques
can be in microglia and neurons, we determined
whether PSAP expression could also be detected in
Fig. 7 Biochemical analysis of interactions of progranulin and prosaposin in MTG brain samples. (a-b). Co-immunoprecipitation of Progranulin
and Prosaposin. a). Western blot control analyses to show interactions of progranulin (PGRN) and prosaposin (PSAP). Immunoprecipitation of
PGRN-overexpressing HEK (HEK and HEK1) cells and AD brain sample with protein G- (goat antibody) or protein A- (rabbit antibody) antibody-
conjugated magnetic beads. Beads were prepared using non-immune goat IgG, goat anti-PGRN and rabbit anti-PSAP. Immunoprecipitated
samples were separated by gel electrophoresis, transferred to membranes, and probed with antibodies to PSAP and PGRN. Samples of total
protein (non-immunoprecipitated) from PGRN-overexpressing HEK (HEK) cells and brain sample (AD) were analyzed as specificity controls.
Samples immunoprecipitated with PGRN antibody contained PSAP, and samples precipitated with PSAP antibody contained PGRN. b). All of the
brain samples from LP, AD and HP cases precipitated with PGRN antibody pulled-down PSAP. A series of cases (n = 5) from each group were
analyzed. Western blot images for both antibodies are shown. (c-f) Biochemical analysis of prosaposin in MTG brain protein extracts. c). Western
blot analysis of total PSAP protein levels in MTG samples. Representative image of western blot demonstrating PSAP protein in samples from LP,
HP and AD cases. The complete images of all samples analyzed for PSAP are shown as Additional file 4: Figure. S4B. D). Scatter plot showing
expression levels of PSAP protein in the different groups. Results represent mean ±S.E.M. Significantly increased levels of PSAP protein were
present in AD case compared to LP and HP cases but not between LP and HP cases. Significant increased levels of PSAP protein in MTG samples
from AD compared to HP (* p < 0.05) and LP (** p < 0.01). e). Positive correlation between PSAP and PGRN protein levels in MTG samples
(Pearson r = 0.4674, p = 0.0070). f). Positive correlation between PSAP and Aβ protein levels in MTG samples (Pearson r = 0.4584, p = 0.0083).
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Fig. 8 (See legend on next page.)
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microglia or astrocytes. Double staining of sections for
PSAP with IBA-1 and CD68 (microglia markers), and
GFAP (astrocyte marker) identified limited amounts of
colocalization (arrows Fig. 8g-i), while all images showed
that most PSAP immunoreactivity was present in neu-
rons. Double staining for CD68 and PSAP of sections
from each group identified plaque-like structures with
significant PSAP immunoreactivity (Fig. 8 J-L), but there
was only small amounts of colocalization with the
CD68-positive microglia infiltrating these plaques.
Examination of plaque structures in low plaque, high
plaque and AD cases stained for PGRN and PSAP (Fig. 9)
showed extensive colocalization in all groups (Fig. 9a-c–LP;
Fig. 9d-f-HP; Fig. 9g-i-AD, but with differences between
disease groups. All PGRN-associated plaque structures
were positive to different extents with PSAP. Measurement
of the degree of colocalization of PGRN and PSAP (as Pear-
son’s correlation efficiency) showed less colocalization in
plaques of AD cases compared to LP cases, but not be-
tween LP and HP or HP and AD (Fig. 9m). The Pearson’s
correlation efficiency values showed a high degree of colo-
calization of PGRN and PSAP. In order to carry out mea-
surements of PGRN and PSAP colocalization, sections
were double-stained for these proteins, but not also for Aβ.
This produced images of approximately equal fluorescent
intensity; however, to illustrate the arrangement of Aβ in
relation to PGRN and PSAP in the different disease groups,
parallel sections from the same cases that were triple-
stained for PGRN (green), PSAP (red) and Aβ (blue) are
also shown (Fig. 9j-LP, Fig. 9k-HP, Fig. 9l-AD). The PGRN-
and PSAP-positive structures in Fig. 9 J-L show the rela-
tively larger Aβ plaques in AD cases compared to LP and
HP cases. The occupied area of PGRN-PSAP plaques dif-
fered significantly between the disease groups. These area
measurements were of PGRN-PSAP/Aβ-occupied areas
not just Aβ- occupied areas. The same measurements were
used to determine the fluorescent intensities of PGRN
(Additional file 7: Figure S7A and S7B) and PSAP immuno-
reactivity (Additional file 7: Figure S7Cand S7D) on plaques
in the different disease groups. The total plaque intensities
of PGRN and PSAP in AD cases were significantly less than
between LP and HP groups (Additional file 7: Figure
S7A and S7C), and similar results were obtained when in-
tensity measures were corrected for plaque size (Additional
file 7: Figure S7B and S7D).
The confocal images of PGRN and PSAP in plaque
structures were further analyzed using computer-assisted
three-dimensional imaging to illustrate colocalization
using Mesh software imaging. These images showed the
Mesh images illustrating the interaction of PGRN and
PSAP in an LP and AD case (white boxes areas in Fig. 9c
and Fig. 9i). Mesh rendering of 3D-modelled images facili-
tate the visualization of the interaction of PGRN (green)
structures with PSAP (red) structures (Fig. 9p and Fig.
9q). Unlike the rendering of PGRN and Aβ (Fig. 4u), the
patterns of PGRN and PSAP interactions suggest close
binding of these two proteins. Similar interactions could
be demonstrated from rendered images produced from
PGRN and PSAP plaque structures from low plaque and
high plaque cases (Fig. 9p and Fig. 9q).
Discussion
The majority of experimental and neuropathological
studies of PGRN have focused on the consequences of
GRN gene mutations or deletion in rodent models. Mu-
tation in one GRN allele resulting in lower levels of
PGRN protein is a cause of frontotemporal lobar degen-
eration (FTLD) and the accompanying clinical syndrome
frontotemporal dementia (FTD) [62]. As PGRN has mul-
tiple cellular properties, the mechanisms that cause neu-
rodegeneration have not definitively been identified.
PGRN deficiencies in animal models are associated with
increased neuroinflammation [17], increased synaptic
pruning [21, 63], and dysregulation of lysosomal func-
tion [14, 64]. The situation for PGRN in AD is different
as increased levels of PGRN in AD brains measured by
ELISA has been reported [19], and confirmed in this
study by western blot measurements. Another study
showed no significant increase in PGRN protein in
frontal cortex of AD brains by western blot, but did de-
tect increased levels of PGRN mRNA in these samples
[34]. The overall aim of this study was to further investi-
gate using human brain samples some of the features of
PGRN interactions with neuropathology identified in
(See figure on previous page.)
Fig. 8 Confocal microscopy of prosaposin localization on plaques and different cell types. (a-c). Aβ (green) (a) and PSAP (red) plaque (b) with
limited colocalization (C – yellow) in an AD case. Scale bar represents 30 μm. (d-f). Comparison of colocalization in plaque of PGRN (green) and
Aβ (blue) (d) with PSAP (red) and Aβ (blue) in triple-stained AD section. Merged images show extensive colocalization of PGRN and PSAP (yellow)
but limited overlap with Aβ-positive structures. Scale bar represents 30 μm. (G-I). Merged images of PSAP (red) immunoreactivity with microglial
markers IBA-1 (g) and CD68 (h) (green) and astrocyte marker GFAP (green) show some expression of PSAP in both cell types (yellow). These
images show that PSAP (red) is predominantly in cells with morphology of neurons. Scale bar represents 10 μm. (j-l). Merged images of CD68
(green) and PSAP (red) on plaques in low plaque case (J), high plaque case (k) and AD case (l). Significant amounts of PSAP immunoreactivity
(red) can be observed on all plaques but with only limited colocalization with CD68 in infiltrating microglia. Scale bar represents 30 μm. (m-n)
Merged images of AT180 (pTau) (green) and PSAP (red) on tangle in low plaque case (M), high plaque case (n) and Alzheimer’s disease case (o).
Very limited amounts of PSAP immunoreactivity (yellow) can be observed on tangles. Panel M and N show intracellular tangles with DAPI-positive
nuclei, while panel O shows extracellular tangle. Scale bar represents 30 μm.
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Fig. 9 Analysis of PGRN and PSAP colocalization on Aβ plaques in MTG tissue sections. Colocalization of PGRN and PSAP with Aβ in plaques of low
plaque, high plaque and Alzheimer’s disease cases. (a-l). Images show representative images of relative patterns of immunoreactivity of PGRN (green),
PSAP (red) and their colocalization with Aβ (blue) in low plaque (a-c, j), high plaque (d-f, k) and Alzheimer’s disease (g-i, l) cases. The magnification of
the images is constant (scale bar represents 30 μm) to show relative sizes of plaques in these disease groups. (m). Scatter plot showing relative
amounts of colocalization of PGRN and PSAP as measured by Pearson’s correlation efficiency calculated using ExColocalization plug-in of Image J
software (n = 9 plaques/group). Results show mean values ±S.E.M. Analysis by one-way ANOVA (* p < 0.05, ns; not significant). Value of 1 indicates
complete colocalization and value of 0 indicates no colocalization. (n). Area measurements of PGRN/PSAP immunoreactive plaques in LP, HP and AD
cases. Three cases/disease group and 6 plaques/case were measured. Results show mean values ±S.E.M. Significant increase in area of PGRN/PSAP
associated plaques were detected in AD samples compared to HP and LP cases. Three-dimensional Imaging of PGRN-PSAP interactions in plaques. (o-
q). Three-dimensional reconstruction image of merged PGRN and PSAP immunoreactive plaques in LP and AD cases of areas highlighted in panel C
(LP) and K (AD) confocal images (panel O). Software modelling using mesh rendering of section of plaque (white boxes) showing close interactions of
PGRN and PSAP in both LP and AD cases (yellow areas). Top view mesh rendering (P) and Side view mesh rendering (Q).
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mice models of AD, particularly the nature of PGRN as-
sociations with Aβ plaques. The common features of
PGRN in human AD brains and AD mouse models are
PGRN immunoreactive structures associated with Aβ
plaques, and cellular expression of PGRN by neurons
and microglia [19, 31–34, 65]. From this study, we
showed the interaction of PGRN with PSAP, a molecule
with similar properties to PGRN, to be a major feature
of PGRN-associated with amyloid plaques.
Increased levels of PGRN in AD brains could be consid-
ered a reparative feature to prevent further neuropathol-
ogy as experimental studies have shown that
supplementation of PGRN in Grn haploinsufficient mice
reduced microglial activation, neuronal lipofuscinosis and
improved lysosomal function [25]. Viral transduction of
PGRN into an AD transgenic mouse model reduced amyl-
oid accumulation, neuroinflammation and synaptic loss
[27], and this treatment protected dopaminergic neurons
in a toxin-induced PD mouse model [26]; however, there
have been conflicting results from other studies of PGRN
in AD mouse models. In one study, reducing PGRN levels
resulted in impaired microglial phagocytosis and increased
amyloid plaque deposition, while overexpressing PGRN in
microglia had the opposite consequence [19]. Using a dif-
ferent AD mouse model (APP/PS1), deficiency of PGRN
was associated with reduced deposition of diffuse amyloid
due to enhancement of microglial phagocytosis caused by
PGRN deficiency increasing expression of microglia TYR-
OBP genes [21]. This study and another observed in-
creased tangle-associated phosphorylated tau with PGRN
deficiency in P301L tau mutation mice [66].
In this report, cellular and pathological localization of
PGRN was carried out with a well-characterized PGRN
antibody raised against a glycosylated recombinant frag-
ment of PGRN corresponding to almost full-length PGRN.
This antibody will be able to recognize multiple epitopes of
PGRN and appeared to have excellent sensitivity for detec-
tion of PGRN in tissue samples. It had been shown to have
excellent specificity with no staining or polypeptide bands
detected against PGRN knock-out cell samples in contrast
to other antibodies [61]. We confirmed its specificity by
peptide absorption with immunohistochemistry and west-
ern blot analyses. This antibody detected polypeptides of
75–80 kDa in brain samples, the expected size for full-
length PGRN. Our studies showed that sensitivity of detec-
tion was enhanced in the absence of reducing agents and
by fixation of western blot membranes with paraformalde-
hyde. With this antibody, we demonstrated expression by
microglia, neurons and in the cerebrovasculature but not
by astrocytes. Staining of structures closely associated with
Aβ plaques but not neurofibrillary tangles was observed. In
a previous study, the predominant PGRN polypeptide de-
tected using a peptide-derived monoclonal antibody had a
molecular weight of approximately 55 kDa, which we
showed corresponded to unglycosylated PGRN [34]. This
study did not detect the abundant species of PGRN of 75–
80 kDa in brain detected in this report. These authors also
detected neurofibrillary tangles positive for PGRN, while
we observed no significant association of PGRN-
immunoreactivity of neurofibrillary tangles identified using
two different antibodies to separate epitopes of phosphory-
lated tau.
A key issue to address in this study is whether the
PGRN immunoreactive structures being identified in
brain sections are full-length PGRN or proteolytically-
processed granulin peptides. Western blot results with
the goat antibody to PGRN identified full-length PGRN
as the most abundantly present in all brain samples,
while lower molecular weight granulin peptides were not
readily detectable, or were at very low abundance. This
antibody has been shown to recognize granulin peptides
if present in samples [61]. A recent study used granulin-
domain antibodies to identify immunoreactive structures
in AD brains similar to what we have characterized [35];
however the granulin sub-domain antibodies used would
have the ability to also detect PGRN, so the issue of the
amount of PGRN compared to granulin in plaque struc-
tures will require further investigation.
It had been hypothesized that a deficit in PGRN might be
an early feature of AD in the prodromal stage [19], and the
increase occurred later in the disease as pathology devel-
oped. We investigated this using pathologically-staged LP,
HP and AD cases. We examined the levels of PGRN pro-
tein by western blot, and quantified the numbers and sizes
of PGRN-associated amyloid plaques in each of these
groups. A limitation to this study was that there were fewer
protein extract samples available compared to fixed tissue
sections, but all of the cases with available protein extract
also had tissue sections. There was no difference in total
brain PGRN protein levels between LP and HP cases, but
there was a difference between these groups in the number
and area of plaques with PGRN-immunoreactive structures.
The presence and increase in numbers of PGRN-positive
plaques suggest that once Aβ plaques form, PGRN be-
comes associated with them. In the LP cases, 7 of the cases
had no Aβ plaques, while the remaining 9 with plaques all
had PGRN-associated with Aβ plaques. In all of the groups,
the plaques without PGRN-associated structures tended to
have a diffuse morphology and were negative for staining
with thioflavin-S, while the plaques with PGRN-associated
structures had thioflavin-S positive, aggregated morpholo-
gies (Fig. 3d).
We investigated the nature of PGRN structures associ-
ated with plaques in terms of their interaction with lyso-
somal proteins as it had been observed using 5xFAD AD
model mice that most PGRN associated with plaques was
present within aberrant accumulations of lysosomes [32]. In
these mice, most plaques had significant amounts of
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LAMP-1, CD68 and other lysosomal proteins associated
with them, with PGRN and LAMP-1 showing significant
colocalization. Our study demonstrated LAMP-1 immuno-
reactivity associated with plaques but only limited
colocalization with PGRN immunoreactivity. CD68 immu-
noreactivity associated with plaques colocalized with PGRN
immunoreactivity, but the majority of plaque-associated
PGRN did not colocalize with these lysosomal proteins.
The question arising from these observations is whether
PGRN associated with plaques was enhancing plaque
development, promoting its removal or was not in a
biologically active form. On account of our biochem-
ical studies showing that PGRN immunoprecipitated
from brain samples pulled down PSAP, the involve-
ment of this protein with PGRN in plaques became
an additional feature of this study.
This study has made a number of observations con-
cerning PSAP in relation to AD pathology. With the hu-
man brain samples available, we were able to examine
PGRN and PSAP changes early in the pathological stages
of plaque and tangle formation. Using these samples for
co-immunoprecipitation studies of human brain sam-
ples, we showed that precipitating PGRN consistently
pulled down PSAP but with little difference between the
different disease groups. This is the first demonstration
of PGRN/PSAP interactions in human brain samples.
These PGRN immunoprecipitated samples were negative
for sortilin [67, 68]; this finding was unexpected as sorti-
lin is enriched in plaques and regulates PGRN levels [53,
69]. Other proteins that did not interact with PGRN
were TMEM106B [34, 70], cathepsin D [71], EphA2 [72]
and BACE-1 [32]. Other proteins have been identified to
interact with PGRN that were not assessed. These in-
clude phospholipase D3 (PLD3) that colocalizes with
PGRN on neuritic plaques [73], and Toll-like receptor-9
whose signaling in macrophages is regulated by granulin
[74]. However, we could detect PSAP binding to cathep-
sin D and BACE-1 in brain samples. This will be investi-
gated in further studies. The possible role of PSAP in
AD has not been adequately addressed. There were no
changes in microglial or neuronal PSAP immunoreactiv-
ity in AD sections compared to those from FTLD cases
due to GRN mutations where neuronal PSAP was re-
duced, but microglia and astrocyte expression was in-
creased [42]. Our findings from this study were
increased levels of PSAP in AD brains, with significant
positive correlation between PGRN and PSAP levels in
all samples. We confirmed PGRN and PSAP interactions
in neurons and microglia, but most significantly might
be the colocalization of PGRN and PSAP associated with
plaque structures. Increased levels of PSAP have been
shown to increase the oligomerization of PGRN [42].
The interaction of PGRN and PSAP into aggregated
structures may result in loss of biological activities, a
feature that will need to be investigated. Even though
there are increased amounts of PGRN and/or PSAP
around plaques, being bound into these structures may
prevent cellular signaling needed for their protective
properties. It had been hypothesized that increased
PGRN should stimulate associated microglia to phago-
cytose and remove the plaques, however if the PGRN is
in a form that does not permit cellular endocytosis,
namely bound with PSAP, excess amounts of inactive
PGRN protein might be hindering plaque removal or
promoting Aβ deposition. We observed that PGRN/
PSAP-positive Aβ plaques in AD cases appeared to ex-
tend beyond the zones of PGRN/PSAP deposits. The
biological properties of PGRN bound with PSAP in
extracellular locations have not been investigated.
The significance of PSAP in neurodegenerative diseases
is just being appreciated. A recent study employing new
proteomics methods identified PSAP as a CSF biomarker
for distinguishing preclinical AD from AD [44]. As PGRN
has been studied as a biomarker for CSF and plasma but
with limited diagnostic utility [30], improved diagnostic
results might occur by combining both of these factors in
biomarker discovery studies. We found most PSAP ex-
pression in brain samples was in neurons, which strongly
colocalized with PGRN. PSAP expression by microglia
and astrocytes was very limited in AD and aged brains but
we observed that most PGRN in plaques colocalized with
PSAP. Induction of microglial and astrocytic PSAP ex-
pression was reported in acute injury. Using the acute cor-
tical stab wound model in mice, a 10-fold increase in
PGRN was detected and a 50% increase in PSAP [42]. Ex-
perimental studies have shown that PSAP can regulate the
levels and aggregation state of PGRN. Reducing levels of
PSAP resulted in increased levels of PGRN in vitro, and
PSAP gene-deficient mice had higher levels of PGRN.
However, PSAP overexpression also induced increased
amounts of aggregated PGRN, but not GRN mRNA [39].
One of the initial questions about PGRN in Aβ plaques
was whether the presence of this factor affected the aggre-
gation and/or removal of the plaques. In vitro experiments
have shown that PGRN can stimulate microglial phagocyt-
osis but the PGRN associated with plaques, which is de-
tectable in sections from non-AD low plaque cases, does
not appear to promote the removal of plaques. PGRN/
PSAP plaques are infiltrated by microglia but these cells
do not appear capable of removing Aβ. Our results seem
to indicate that Aβ deposition increases in AD brains irre-
spective of the presence of PGRN and PSAP.
In summary, we have described features of PGRN and
PSAP in a staged series of human brain tissue samples,
and in particular PGRN-positive plaques. The most no-
ticeable feature was the interactions in plaques of PGRN
with PSAP. It is possible that PGRN/PSAP interactions
with plaques could result in sequestration of toxic forms
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of Aβ, however, to address this as a mechanism, further
studies will determine whether PGRN interactions with
PSAP affect its neuroprotective and anti-inflammatory
properties. This could be an important issue when deter-
mining whether PGRN supplementation will be useful. If
the excess PGRN protein becomes absorbed by plaques
in AD cases, it might not have the expected neuropro-
tective properties. The possible role for PSAP supple-
mentation can also be considered. Both PGRN and
PSAP have similar growth factor and lysosomal regula-
tory functions, but the consequences of PSAP supple-
mentation has not been explored.
Conclusion
From these findings, it can be concluded that the presence
of neuroprotective molecules PGRN and PSAP on Aβ pla-
ques do not prevent the formation of these structures. Sig-
nificant interactions between these molecules were
demonstrated biochemically, and by immunohistochemi-
cal techniques in neurons and also associated with Aβ pla-
ques. Secreted forms of PGRN have multiple protective
and anti-inflammatory properties, but these might not be
evident when this protein is deposited with PSAP around
Aβ plaques. Increased total protein levels of PGRN and
PSAP was evident in AD samples but not those with less
pathology, but the presence of PGRN and PSAP on most
plaques in low pathology control cases with fewer smaller
plaques indicate this is an earlier event in development of
AD pathology. Binding of these proteins on Aβ plaques
might have ameliorating effects of Aβ toxicity on sur-
rounding cells, or it might be hindering the removal of Aβ
plaque by infiltrated microglia.
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Additional file 1 Figure S1. (A-B). PGRN peptide absorption of goat
anti-PGRN antibody (AF2420). Low magnification images demonstrating
absence of immunoreactive structures in MTG (AD case) reacted with
PGRN antibody preabsorbed with PGRN peptide (A)(+PGRN peptide) and
demonstration of significant immunoreactivity in parallel section from
same case reacted with non-peptide antibody (B)(−PGRN peptide). Scale
bars represent 200 μm. (C-D). PSAP peptide absorption of rabbit anti-
PSAP antibody (AF8470). Low magnification images demonstrating
absence of immunoreactive structures in MTG (AD case) reacted with
PSAP antibody preabsorbed with PSAP peptide (C)(+PSAP peptide) and
demonstration of significant immunoreactivity in parallel section from
same case reacted with non-peptide antibody (D)(−PSAP peptide). Scale
bars represent 200 μm.
Additional file 2 Figure S2. Western blot characterization of PGRN
polypeptides detected with goat anti-PGRN antibody (AF2420). A).
Absorption of PGRN polypeptides with peptide-absorbed PGRN antibody.
Western blot images of purified PGRN peptide (PGRN), AD brain protein
extract (AD) and THP macrophage cell protein extracts (THP) detected
with PGRN peptide-absorbed antibody (+Peptide) or non-absorbed antibody
(−Peptide). Peptide absorption resulted in almost complete absence of PGRN
polypeptide bands. B). Detection of PGRN by western blots is sensitive to
reducing agents. Western blots comparing polypeptide bands in protein
extracts of samples prepared with DTT (+) or without DTT (−) as reducing
agent. Samples: PGRN; purified recombinant PGRN protein. LAN-5; neuronal
cells. THP; THP-1 derived macrophages. Brain; AD brain samples. Blots were
probed with goat anti-PGRN antibody (R&D Systems, AF2420:50 ng/ml). C).
Sensitivity of detection of PGRN polypeptides in brain samples is enhanced
by membrane fixation with paraformaldehyde vapors. Western blot images
of brain protein samples from low plaque (LP) and Alzheimer’s disease (AD)
cases separated under identical conditions without reducing agents. One
membrane was fixed with paraformaldehyde vapors (+PFA) compared to
membrane not PFA treated (−PFA). Sensitivity of detection is enhanced in
PFA fixed membranes. Blots were probed with goat anti-PGRN antibody
(R&D Systems, AF2420:50 ng/ml). D). Identification of deglycosylated forms
of PGRN. Protein extracts from THP macrophage cells (THP), and LP and AD
brain samples were treated with deglycosylation enzyme PNGaseF (+)
or control treated (−). Deglycosylation treatment resulted in increased
levels of 55 kDa polypeptides and reduced amounts of ~ 75 kDa
PGRN band. Blots were probed with goat anti-PGRN antibody (R&D
Systems, AF2420:50 ng/ml).
Additional file 3 Figure S3 Limited colocalization of PGRN with
markers defining neurites and neuritic plaques. A-C): Confocal image of
PGRN (green)(A) immunoreactivity associated with a neuritic plaque
identified with pTau antibody AT180 (B) with merged image (C) in an AD
case showing no colocalization of staining. DAPI staining identified nuclei
and also highly aggregated amyloid within plaques. Scale bar represents
20 μm. D-F): Confocal image of PGRN (green)(D) immunoreactivity
associated with neurites and neuritic plaque identified with pan-
neurofilament antibody SMI312 (E) with merged DAPI-stained image (F)
in an AD case showing limited colocalization of staining. Scale bar represents
20 μm. G-I): Confocal image of PGRN (green)(G) immunoreactivity associated
with neurites and neuritic plaque identified with synaptophysin antibody (H)
with merged DAPI-stained image (I) in an AD case showing no colocalization
of staining. Scale bar represents 20 μm. These images were acquired using a
Leica SP8 confocal microscope.
Additional file 4 Figure S4. Complete western blot images of MTG
protein samples. A). Complete western blot images of MTG brain
sauremples probed with antibody to detect PGRN polypeptides in Low
plaque (LP), high plaque (HP) and AD samples. Major PGRN polypeptide
bands detected at approximately 75–80 kDa, with less intense bands at 55
kDa. These blots showed absence of low molecular weight granulin
peptides. Top Image: Shorter exposure of western blot. Lower Image: Longer
exposure of western blot to demonstrate if granulin peptides were present.
B). Complete western blot images of MTG brain samples probed with
antibody to detect PSAP polypeptides in Low plaque (LP), high plaque (HP)
and AD samples. Major PSAP polypeptide bands detected at approximately
72 kDa. Additional polypeptide bands are detectable with image
enhancement indicating detection of PSAP-derived saposin peptides. Top
Image: Shorter exposure of western blot. Lower image: Longer exposure of
western blot images of MTG brain samples probed with antibody to detect
PSAP polypeptides. Bands with molecular weights of saposin peptides are
indicated. These were noticeable in AD samples.
Additional file 5 Figure S5. Additional analysis and controls for
proteins analyzed by co-immunoprecipitation or colocalization with
progranulin and prosaposin A-B) Composite western blot of additional
potential PGRN-interacting proteins using Protein A or Protein G beads
conjugated with normal goat IgG, or antibodies to PGRN, PSAP, sortilin,
TMEM106B, cathepsin D and beta secretase-1 (BACE-1) (panel B).
Comparison was carried out with non-immunoprecipitated total protein
extracts of brain samples analyzed on the same blots. Sortilin: Antibody
detected polypeptide with expected molecular weight in brain samples.
No sortilin immunoreactive bands were present in PGRN IP samples but a
faint band was detected in PSAP IP samples. TMEM106B: Antibody
detected polypeptide with expected molecular weight in brain samples.
No TMEM106B immunoreactive bands were present in PGRN or PSAP
immunoprecipitated samples. Cathepsin D: Antibody detected polypeptide
with expected molecular weight in brain samples. No cathepsin D
immunoreactive bands were present in PGRN IP samples but a faint band
was detected in PSAP IP samples. BACE1: Analysis showed that samples
precipitated with PGRN conjugated beads did not pull down BACE1
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immunoreactive bands but band detected in PSAP-immunoprecipitated
samples. BACE-1 conjugated beads included as positive control. (SH –
extract of neuronal SH-SY5Y cells). C) Scatter blot showing ratio of
expression levels of PSAP to amounts of PGRN in immunoprecipitated
samples. The ratio of PSAP to PGRN present in samples immunoprecipitated
with antibody to PGRN was not significantly different between disease
groups. Confocal microscopy of PGRN-positive plaque structures with
indicated antibodies. D-F) PGRN (green) and Sortilin (red) immunoreactivity
was detected in plaques but there was no detectable colocalization (F).
Scale bars represent 30 μm. G-I) PGRN (green) and TMEM106B (red)
immunoreactivity was detected in or around plaques but there was no
detectable colocalization (I). Scale bars represent 30 μm. J-L) PGRN (green)
and Cathepsin D (red) immunoreactivity. There was no detectable
colocalization (L). Scale bars represent 30 μm. M-O) PGRN (green) and BACE
(red) immunoreactivity was detected on cells around plaques but there was
no detectable colocalization in cells and on plaques (O). Scale bars represent
30 μm.
Additional file 6 Figure S6 Complete western blot images of
immunoprecipitated brain and cell samples to identify presence of
granulin or saposin peptides. A) Complete western blot image of brain
samples immunoprecipitated with PGRN antibody conjugated magnetic
beads and detected with antibody to PSAP. The blots showed no
evidence of lower molecular weight saposin peptides. B) Complete
western blot image of brain samples immunoprecipitated with PGRN
antibody conjugated magnetic beads and detected with antibody to
PGRN. The blots showed no evidence of lower molecular weight granulin
peptides. C) Complete western blot images of PGRN-overexpressing HEK
and brain samples (AD) immunoprecipitated with magnetic beads
conjugated with control normal goat immunoglobulin (goat IgG), or
PGRN or PSAP antibodies and probed with antibody to PGRN. Image
shows that granulin peptides could be minimally detected only in HEK
cells expressing high levels of PGRN protein. Blot also shows total extracts
from SH-SY5Y differentiated neurons (SY) and AD brain analyzed in
parallel showing no detectable granulin peptides.
Additional file 7 Figure S7: Fluorescent plaque intensities of PGRN and
PSAP in MTG sections between disease groups. A) Fluorescent intensity of
PGRN immunoreactivity on plaques between LP, HP and AD cases. Six
plaques were measured in 3 cases in each group (n = 18 plaques/group).
Results represent mean + SEM of total fluorescent intensity. Results analyzed
by one-way ANOVA with Neuman-Keuls post-hoc test between groups. **
p < 0.01, ns: not significant. B) Area-adjusted fluorescent intensity of PGRN
immunoreactivity on plaques between LP, HP and AD cases of PGRN-PSAP
positive plaques. Six plaques were measured in 3 cases in each group (n =
18 plaques/group). Results represent mean ± S.E.M. of average fluorescent
intensity adjusted for plaque area (Fig. 9N). Results analyzed by one-way
ANOVA with Neuman-Keuls post hoc test between groups. **** p < 0.0001,
** p < 0.01, ns: not significant. C) Fluorescent intensity of PSAP immunoreactivity
on plaques between LP, HP and AD cases. Six plaques were measured in 3
cases in each group (n = 18 plaques/group). Results represent mean ±S.E.M. of
total fluorescent intensity. Results analyzed by one-way ANOVA with Neuman-
Keuls post hoc test between groups. **** p < 0.0001, ns: not significant. D)
Area-adjusted fluorescent intensity of PSAP immunoreactivity on plaques
between LP, HP and AD cases of PGRN-PSAP positive plaques. Results represent
mean+±S.E.M. of average fluorescent intensity adjusted for plaque area
measures (Fig. 9N). Six plaques were measured in 3 cases in each
group (n = 18 plaques/group). Results analyzed by one-way ANOVA
with Neuman-Keuls post-hoc test between groups. **** p < 0.0001,
* p < 0.05, ns: not significant.
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